Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; 17 of the 31 sources its claims cite were checked for support.

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Open access

Abstract

Abstract Background Murine double minute 2 (MDM2) inhibitors reactivate wild-type p53 and are a promising therapy for glioblastoma, IDH-wildtype (GBM). Brigimadlin is a highly potent MDM2 inhibitor being tested in a phase 0/1 clinical trial in combination with radiation in GBM. Methods Brigimadlin pharmacokinetics, pharmacodynamics, and efficacy were evaluated in GBM patient-derived xenografts (PDXs). Results In vitro, brigimadlin impaired viability in TP53 wild-type GBM with an IC50 of 0.8-6.6 nmol/L, but sensitivity did not correlate with MDM2 amplification. In vivo, MDM2 amplification was highly correlated with efficacy. In subcutaneous PDXs, 1 or 2 mg/kg brigimadlin dosed weekly was highly effective in 2 MDM2-amplified PDXs. At 2 mg/kg, brigimadlin delayed tumor regrowth by >5-fold in the MDM2-amplified PDXs compared to 1.5-fold in a non-amplified PDX. In orthotopic PDXs, efficacy was more limited, but 2 mg/kg brigimadlin enhanced the response to fractionated radiation in MDM2-amplified PDXs. Consistent with blood-brain barrier efflux limiting drug distribution, 2 mg/kg brigimadlin extended survival by >5-fold in an MDM2-amplified orthotopic PDX established in Rag1−/−Abcb1a−/− Abcg2−/− mice. In pharmacodynamic studies, p53 target genes were upregulated at both subtherapeutic and therapeutic dose levels, and the extent of activation did not correlate with MDM2 status. Concentrations of brigimadlin in tumor tissue were approximately 10-fold higher in MDM2-amplified tumors, and intracellular drug levels directly correlated with drug-dependent MDM2 upregulation, suggesting target binding affects drug accumulation. Conclusions Brigimadlin is highly effective in MDM2-amplified GBM when adequate drug levels are achieved in tumor tissue. MDM2 amplification impacts both treatment efficacy and intratumoral drug accumulation.

Overview

CoChat Summary

TL;DR

Brigimadlin is highly effective in MDM2-amplified glioblastoma patient-derived xenografts when adequate intratumoral drug levels are achieved, but orthotopic efficacy is limited by blood-brain barrier efflux. MDM2 amplification is associated with both greater treatment efficacy and higher intratumoral brigimadlin accumulation.

Key findings

  • In vitro, brigimadlin impaired viability in TP53 wild-type GBM lines with IC50 0.8–6.6 nmol/L, but sensitivity did not correlate with MDM2 amplification; the MDM4-amplified GBM8 line showed limited response and the TP53-mutant GBM120 line was highly resistant.
  • In subcutaneous PDXs, 1 or 2 mg/kg weekly brigimadlin was highly effective in 2 MDM2-amplified PDXs; at 2 mg/kg, median time-to-endpoint was 80 days vs 15 days in GBM108 and 57 days vs 11 days in GBM143, compared with 12 days vs 8 days in non-amplified GBM14. Tumor-to-plasma ratios were 12.5 (GBM108), 5.8 (GBM143), and 0.71 (GBM14).
  • In orthotopic GBM108, 2 mg/kg brigimadlin extended median survival to 56 days vs 41 days with vehicle; in efflux-deficient Rag1−/−Abcb1a−/−Abcg2−/− mice, 2 mg/kg extended survival beyond 365 days vs 70 days with vehicle, with brain-to-plasma ratio 0.38 vs 0.03 in nude mice.
  • p53 target genes were upregulated at subtherapeutic and therapeutic doses, and the extent of activation did not correlate with MDM2 status; intratumoral brigimadlin concentrations were approximately 10-fold higher in MDM2-amplified tumors, and intracellular drug levels correlated with drug-dependent MDM2 upregulation.

Methods

  • In vitro studies used short-term GBM PDX cultures; viability was measured after 7 days with brigimadlin 0–100 nmol/L by CellTiter-Glo 3D, with Western blot and qRT-PCR for p53 pathway markers and LC-MS/MS for intracellular drug levels.
  • Subcutaneous and orthotopic PDX studies used athymic nude or double-knockout mice; brigimadlin was given weekly by oral gavage, with or without fractionated radiation (2 Gy × 10 fractions), and endpoints were tumor volume >3× initial or moribund.
  • Drug concentrations in plasma, brain, and tumor were measured by LC-MS/MS; analyses included t-tests/rank-sum, 4-parameter log-logistic IC50 estimation, Kaplan-Meier/log-rank survival comparisons, and linear regression, with P < .05 considered significant.

Limitations

  • Stated: orthotopic PDXs are limited as BBB models because they are smaller, show varying infiltration into normal brain, and typically lack the proliferative vasculature of human GBM, so BBB disruption is less heterogeneous than in patients.
  • Stated: siRNA did not achieve sufficient MDM2 knockdown to validate the accumulation mechanism; recurrent tumors were not evaluated for TP53 mutation; the free-fraction target-concentration approach depends on accurate free-fraction measurement and does not account for treatment duration or genotype-related variability.
  • Evident from the text: murine p53-MDM2 is insensitive to existing MDM2 inhibitors, so mouse exposures may exceed clinically achievable levels due to human toxicity; PK/PD sampling used a single 24-hour timepoint; gene expression analyses showed high variability across replicates.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/noajnl/vdaf259

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Effects of brigimadlin in vitro. (A) Impact of brigimadlin on cell viability. PDX short-term cultures were treated with varying doses of brigimadlin (0-100 nmol/L) and cell viability evaluated using the CellTiter-Glo 3D assay after 7 days. NR, not reached. (B) Time course of p53 pathway modulation. Explant cultures were treated with 30 nmol/L brigimadlin and modulation of the p53 pathway over time (0, 6, 16, 24, 48 h) evaluated by Western blot. (C and D) Expression of p53 target genes. Explant cultures were treated with brigimadlin (0, 3, 10 nmol/L) for 6 h ± 5Gy RT and expression of p53 target genes (C) CDKN1A (p21) and (D) BBC3 (PUMA) evaluated by qRT-PCR. At least 3 independent experiments were performed for each PDX with mean ± SEM shown. GBM, glioblastoma; PDX, patient-derived xenograft; qRT-PCR, quantitative reverse transcription PCR; RT, radiation therapy. *P < .05.
Figure 1. Effects of brigimadlin in vitro. (A) Impact of brigimadlin on cell viability. PDX short-term cultures were treated with varying doses of brigimadlin (0-100 nmol/L) and cell viability evaluated using the CellTiter-Glo 3D assay after 7 days. NR, not reached. (B) Time course of p53 pathway modulation. Explant cultures were treated with 30 nmol/L brigimadlin and modulation of the p53 pathway over time (0, 6, 16, 24, 48 h) evaluated by Western blot. (C and D) Expression of p53 target genes. Explant cultures were treated with brigimadlin (0, 3, 10 nmol/L) for 6 h ± 5Gy RT and expression of p53 target genes (C) CDKN1A (p21) and (D) BBC3 (PUMA) evaluated by qRT-PCR. At least 3 independent experiments were performed for each PDX with mean ± SEM shown. GBM, glioblastoma; PDX, patient-derived xenograft; qRT-PCR, quantitative reverse transcription PCR; RT, radiation therapy. *P < .05.CC BY-NC · PubMed Central
Figure 2. Efficacy, PK, and PD relationships in GBM108, GBM143, and GBM14 subcutaneous PDX. Mice with established (A) GBM108, (B) GBM143, or (C) GBM14 subcutaneous tumors were randomized to treatment with vehicle or brigimadlin (0.125, 0.25, 0.5, 1, or 2 mg/kg) once weekly for 4 weeks (n = 5-6 per group) and tumor volume monitored until the defined endpoint (>3× initial volume). Survival is shown relative to the start of brigimadlin dosing. (D-I) Mice with established GBM108, GBM143, or GBM14 subcutaneous tumors were treated with a single dose of brigimadlin with plasma and tumor tissue harvested after 24 hours. p53 target gene modulation was evaluated by qRT-PCR in (D) GBM108, (E) GBM143, and (F) GBM14. In the same animals, drug levels measured by LC-MS/MS in (G) GBM108, (H) GBM143, and (I) GBM14. PD, pharmacodynamic; PK, pharmacokinetic; qRT-PCR, quantitative reverse transcription PCR; T:P, tumor-to-plasma concentration ratio for each PDX. *P < 0.05, **P < 0.01, ***P < 0.001 relative to vehicle.
Figure 2. Efficacy, PK, and PD relationships in GBM108, GBM143, and GBM14 subcutaneous PDX. Mice with established (A) GBM108, (B) GBM143, or (C) GBM14 subcutaneous tumors were randomized to treatment with vehicle or brigimadlin (0.125, 0.25, 0.5, 1, or 2 mg/kg) once weekly for 4 weeks (n = 5-6 per group) and tumor volume monitored until the defined endpoint (>3× initial volume). Survival is shown relative to the start of brigimadlin dosing. (D-I) Mice with established GBM108, GBM143, or GBM14 subcutaneous tumors were treated with a single dose of brigimadlin with plasma and tumor tissue harvested after 24 hours. p53 target gene modulation was evaluated by qRT-PCR in (D) GBM108, (E) GBM143, and (F) GBM14. In the same animals, drug levels measured by LC-MS/MS in (G) GBM108, (H) GBM143, and (I) GBM14. PD, pharmacodynamic; PK, pharmacokinetic; qRT-PCR, quantitative reverse transcription PCR; T:P, tumor-to-plasma concentration ratio for each PDX. *P < 0.05, **P < 0.01, ***P < 0.001 relative to vehicle.CC BY-NC · PubMed Central
Figure 3. Cellular accumulation of brigimadlin in vitro. (A and B) Short-term cultures from GBM14, GBM108, and GBM143 PDX were treated with placebo or 30 nmol/L brigimadlin for 0.5 or 6 hours. Cell lysates were analyzed in parallel for (A) protein expression by Western blot and (B) drug levels by LC-MS/MS. Mean ± SEM shown. (C) Proposed mechanism of drug accumulation in MDM2-amplified GBM. In untreated cells, MDM2 ubiquitinates (Ub) and targets p53 for proteasomal degradation. Brigimadlin disrupts the p53-MDM2 interaction, preventing degradation. p53 translocates to the nucleus and drives expression of MDM2, which is markedly upregulated at 6 hours. In MDM2-amplified tumors, the highly expressed MDM2 protein binds brigimadlin, leading to cellular accumulation. Created in BioRender. Vaubel, R. (2025) https://BioRender.com/dw8yulp. MDM2, murine double minute 2.
Figure 3. Cellular accumulation of brigimadlin in vitro. (A and B) Short-term cultures from GBM14, GBM108, and GBM143 PDX were treated with placebo or 30 nmol/L brigimadlin for 0.5 or 6 hours. Cell lysates were analyzed in parallel for (A) protein expression by Western blot and (B) drug levels by LC-MS/MS. Mean ± SEM shown. (C) Proposed mechanism of drug accumulation in MDM2-amplified GBM. In untreated cells, MDM2 ubiquitinates (Ub) and targets p53 for proteasomal degradation. Brigimadlin disrupts the p53-MDM2 interaction, preventing degradation. p53 translocates to the nucleus and drives expression of MDM2, which is markedly upregulated at 6 hours. In MDM2-amplified tumors, the highly expressed MDM2 protein binds brigimadlin, leading to cellular accumulation. Created in BioRender. Vaubel, R. (2025) https://BioRender.com/dw8yulp. MDM2, murine double minute 2.CC BY-NC · PubMed Central
Figure 4. Effects of brigimadlin in GBM108 orthotopic PDX. Orthotopic GBM108 PDX were established in athymic nude mice and randomized to treatment with vehicle or brigimadlin (0.25, 0.5, 1, 2, or 10 mg/kg) once weekly for 4 weeks (n = 10 per group) and monitored until moribund. (B and C) Mice with established GBM108 orthotopic tumors were treated with a single dose of brigimadlin. Plasma, normal brain, and tumor tissue harvested after 24 hours. (B) p53 target gene expression was evaluated in tumor tissue by qRT-PCR. (C) In the same animals, drug levels were measured by LC-MS/MS. PDX, patient-derived xenograft; qRT-PCR, quantitative reverse transcription PCR. *P < 0.05, **P < 0.01, ***P < 0.001 relative to vehicle.
Figure 4. Effects of brigimadlin in GBM108 orthotopic PDX. Orthotopic GBM108 PDX were established in athymic nude mice and randomized to treatment with vehicle or brigimadlin (0.25, 0.5, 1, 2, or 10 mg/kg) once weekly for 4 weeks (n = 10 per group) and monitored until moribund. (B and C) Mice with established GBM108 orthotopic tumors were treated with a single dose of brigimadlin. Plasma, normal brain, and tumor tissue harvested after 24 hours. (B) p53 target gene expression was evaluated in tumor tissue by qRT-PCR. (C) In the same animals, drug levels were measured by LC-MS/MS. PDX, patient-derived xenograft; qRT-PCR, quantitative reverse transcription PCR. *P < 0.05, **P < 0.01, ***P < 0.001 relative to vehicle.CC BY-NC · PubMed Central
Figure 5. Efficacy of brigimadlin ± radiotherapy in orthotopic PDX. Mice with established orthotopic (A) GBM108, (B) GBM143, (C) GBM14, or (D) GBM40 tumors were treated with brigimadlin (2 mg/kg weekly × 2 or 12 doses) ± radiotherapy (2 Gy × 10 fractions) and monitored until moribund. PDX, patient-derived xenograft.
Figure 5. Efficacy of brigimadlin ± radiotherapy in orthotopic PDX. Mice with established orthotopic (A) GBM108, (B) GBM143, (C) GBM14, or (D) GBM40 tumors were treated with brigimadlin (2 mg/kg weekly × 2 or 12 doses) ± radiotherapy (2 Gy × 10 fractions) and monitored until moribund. PDX, patient-derived xenograft.CC BY-NC · PubMed Central
Figure 6. Efficacy of brigimadlin in orthotopic PDX established in efflux deficient mice. (A) Drug levels in plasma and normal brain were evaluated by LC-MS/MS in athymic nude and DKO (Rag-null Abcb1a−/− Abcg2g−/−) mice 24 hours after a single 2 mg/kg dose of brigimadlin. B:P, brain-to-plasma ratio. (B) GBM108 orthotopic PDX were established in DKO mice and randomized to treatment with vehicle or brigimadlin (0.25, 0.5, 1, or 2 mg/kg) once weekly for 4 weeks (n = 10 per group) and monitored until moribund. (C) GBM14 orthotopic PDX were established in DKO mice, randomized to treatment with placebo, brigimadlin (2 mg/kg weekly × 2 doses), radiation (RT, 2 Gy × 10 fractions), or combined treatment (n = 5-6 per group), and monitored until moribund. DKO, Double knockout; PDX, patient-derived xenograft; RT, radiation therapy.
Figure 6. Efficacy of brigimadlin in orthotopic PDX established in efflux deficient mice. (A) Drug levels in plasma and normal brain were evaluated by LC-MS/MS in athymic nude and DKO (Rag-null Abcb1a−/− Abcg2g−/−) mice 24 hours after a single 2 mg/kg dose of brigimadlin. B:P, brain-to-plasma ratio. (B) GBM108 orthotopic PDX were established in DKO mice and randomized to treatment with vehicle or brigimadlin (0.25, 0.5, 1, or 2 mg/kg) once weekly for 4 weeks (n = 10 per group) and monitored until moribund. (C) GBM14 orthotopic PDX were established in DKO mice, randomized to treatment with placebo, brigimadlin (2 mg/kg weekly × 2 doses), radiation (RT, 2 Gy × 10 fractions), or combined treatment (n = 5-6 per group), and monitored until moribund. DKO, Double knockout; PDX, patient-derived xenograft; RT, radiation therapy.CC BY-NC · PubMed Central

Verification

Claims the paper makes

13 Valid · 0 Not valid · 12 Not checked · 101 Own results and interpretations

71 more claims

Create a free account to see all 126 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 47

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 29 references

Metadata

Authors
Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., Hu, Z., Ott, L. L., Carlson, B. L., Bakken, K. K., Pasa, T., Sarkaria, N. R., Talele, S., Eckel-Passow, J. E., Sini, P., Elmquist, W. F., & Sarkaria, J. N.
Affiliations
  • Mayo Clinic (US)
  • University of Minnesota (US)
  • Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN,
  • Boehringer Ingelheim (Austria) (AT)
Corresponding author
Sarkaria, Jann N
Venue
Neuro-Oncology Advances
Published
2025-12-15
Volume
8
Issue
1
Pages
vdaf259-vdaf259
ISSN
2632-2498 (ISSN-L)
OpenAlex
W4417413993
Cited by
0
References
29
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Neuro-Oncology Advances (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
Funders
Boehringer Ingelheim, National Institutes of Health/National Cancer Institute (U19-CA264362)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
brigimadlin, MDM2 inhibitors, glioblastoma, patient-derived xenografts, MDM2 amplification, p53 reactivation, pharmacokinetics, pharmacodynamics, intratumoral drug accumulation, fractionated irradiation, orthotopic xenograft, tumor regrowth, p53 target genes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. https://app.cochat.ai/papers/10.1093/noajnl/vdaf259
The paper
Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., Hu, Z., Ott, L. L., Carlson, B. L., Bakken, K. K., Pasa, T., Sarkaria, N. R., Talele, S., Eckel-Passow, J. E., Sini, P., . . . Sarkaria, J. N. (2026). Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdaf259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.